Tuesday, July 1, 2025 7/1/2025

Developing chemoproteomic approaches to decipher the regulatory network of LRH-1, a nuclear receptor implicated in hepatic metabolism

Award Number: F31DK126394
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 09/01/2020
PERIOD OF PERFORMANCE END DATE: 08/31/2022

Group Awards By:

View Award Description

Developing chemoproteomic approaches to decipher the regulatory network of LRH-1, a nuclear receptor implicated in hepatic metabolism - Project Summary and Abstract: Liver receptor homolog-1 (LRH-1; NR5A2) is a phospholipid-sensing nuclear receptor (NR) expressed predominantly in the liver, pancreas, and ovaries that plays an important role in metabolic physiologies and pathophysiologies. Specifically, it has been characterized to regulate bile acid metabolism, cholesterol homeostasis, and steroidogenesis, and in turn is involved in various disease states such as type 2 diabetes, atherosclerosis, nonalcoholic fatty liver disease as well as a multitude of cancers. These diseases are all risk factors for metabolic syndrome that affects nearly a third of the American population. This represents a significant health concern as individuals diagnosed with metabolic syndrome have increased risk for developing cardiovascular diseases as well as hepatocellular, gastric, and colon cancers; cancers that have been associated with overexpression of LRH-1. This suggests LRH-1 to be a promising therapeutic target for such metabolic diseases and cancers. However, a lack of a wholistic understanding of the receptors regulatory mechanism presents a significant limitation to the success of LRH-1 as a therapeutic target. This propels the need to develop effective and specific chemical tools to modulate the receptor’s activity and expand our knowledge of its role in both healthy and disease pathways. Similarly to other NRs, LRH-1’s activity is tightly regulated via a multitude of pathways including ligand binding, DNA binding, cellular localization, post- translational modifications (PTMs), and coregulator interactions. However, unlike many other NRs, LRH-1 binds DNA as a monomer and a specific candidate endogenous ligand has yet to be identified. Rather, LRH-1 has been shown to bind an assortment of phospholipids in order to differentially control downstream signaling pathways. Hence, the interplay of additional complementary or conflicting regulatory pathways are essential for tight control of LRH-1 activity. Changes in these regulatory pathways leads to aberrant receptor activity contributing to disease pathophysiology. While the use of chemical approaches to probe NRs in metabolism has increased over the years, the use of chemoproteomics in this area remains limited. Proteomic analysis of NRs remains problematic as NRs are relatively low abundant and tightly bound to chromatin. As such, there is a need for tools to capture endogenous LRH-1 and LRH-1 transcriptional complexes to better understand LRH-1’s ability to control normal physiology or drive pathological processes. I propose the following specific aims develop novel methodologies and extend the understanding of LRH-1 regulatory mechanisms. In Aim 1, I will establish three LRH-1 specific probes to more efficiently probe and/or capture LRH-1 and LRH-1 transcriptional complexes. These include a biotinylated LRH-1 response element oligo probe, a modified DLPC biotin probe, and SR1848, small molecule inhibitor of LRH-1. In Aim 2, I will probe LRH-1 with SR1848 or Cpd3 to repress receptor activity and DLPC or RJW101 to drive receptor activity to observe differentially regulated PTMs and coregulators as well as understand how they communicate to regulate LRH-1 trafficking and subsequent signaling.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = -$13,774 )
2023	2021	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	3	6/20/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	-$12,124
2023	2021	SCRIPPS RESEARCH INSTITUTE, THE	130 SCRIPPS WAY	JUPITER	FL	33458	PALM BEACH	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	5/15/2023	NON-COMPETING CONTINUATION	-$1,650
														Subtotal = -$13,774

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2021	SCRIPPS RESEARCH INSTITUTE, THE	130 SCRIPPS WAY	JUPITER	FL	33458	PALM BEACH	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	3/22/2022	NON-COMPETING CONTINUATION	-$12,124
2022	2021	SCRIPPS RESEARCH INSTITUTE, THE	130 SCRIPPS WAY	JUPITER	FL	33458	PALM BEACH	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	002	2	4/6/2022	NON-COMPETING CONTINUATION	$0
2022	2021	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	3	3/22/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$12,124
2022	2021	UNIVERSITY OF FLORIDA	1523 UNION RD RM 207	GAINESVILLE	FL	32611	ALACHUA	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	003	3	4/6/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $33,036 )
2021	2021	SCRIPPS RESEARCH INSTITUTE, THE	130 SCRIPPS WAY	JUPITER	FL	33458	PALM BEACH	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	7/23/2021	NON-COMPETING CONTINUATION	$33,036
														Subtotal = $33,036

Issue Date FY: 2020 ( Subtotal = $32,520 )
2020	2020	SCRIPPS RESEARCH INSTITUTE, THE	130 SCRIPPS WAY	JUPITER	FL	33458	PALM BEACH	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	8/25/2020	NEW	$32,520
2020	2020	SCRIPPS RESEARCH INSTITUTE, THE	130 SCRIPPS WAY	JUPITER	FL	33458	PALM BEACH	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	1	8/25/2020	NEW	$0
														Subtotal = $32,520

Grand Total All Awards = $51,782

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Developing chemoproteomic approaches to decipher the regulatory network of LRH-1, a nuclear receptor implicated in hepatic metabolism

Award Number: F31DK126394

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 09/01/2020

PERIOD OF PERFORMANCE END DATE: 08/31/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer